Quick Answer
ARROWHEAD PHARMACEUTICALS, INC. reported Diluted EPS of $0.01 per share (loss) for fiscal year 2025.
ARROWHEAD PHARMACEUTICALS, INC. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.01 | +99.8% |
| 2024 | -$5.00 | -160.4% |
| 2023 | -$1.92 | -15.0% |
| 2022 | -$1.67 | -22.8% |
| 2021 | -$1.36 | -61.9% |
| 2020 | -$0.84 | -221.7% |
| 2019 | $0.69 | +206.2% |
| 2018 | -$0.65 | -38.3% |
| 2017 | -$0.47 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | $0.22 | +115.8% | +117.5% |
| June 30, 2025 | -$1.26 | +8.7% | -145.8% |
| March 31, 2025 | $2.75 | +369.6% | +297.8% |
| December 31, 2024 | -$1.39 | -12.1% | -0.7% |
| June 30, 2024 | -$1.38 | -43.7% | -35.3% |
| March 31, 2024 | -$1.02 | -326.7% | +17.7% |
| December 31, 2023 | -$1.24 | -217.9% | -29.2% |
| June 30, 2023 | -$0.96 | -41.2% | -313.3% |
- ARROWHEAD PHARMACEUTICALS, INC. showed an increase of +99.8% in Diluted EPS compared to the prior fiscal year.
- Over the 2017–2025 period, ARROWHEAD PHARMACEUTICALS, INC.’s diluted eps has grown by 97.9% (from $0.47 per share (loss) to $0.01 per share (loss)).
- The most recent figure is from ARROWHEAD PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on November 25, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: